Medifast, Inc. (MED) Stock Competitors & Peer Comparison

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, ROL has a market cap of 20.8B. Regarding current trading prices, MED is priced at $10.51, while ROL trades at $43.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas ROL's P/E ratio is 37.96. In terms of profitability, MED's ROE is -0.10%, compared to ROL's ROE of +0.37%. Regarding short-term risk, MED is more volatile compared to ROL. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check ROL's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, SCI has a market cap of 10.5B. Regarding current trading prices, MED is priced at $10.51, while SCI trades at $75.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas SCI's P/E ratio is 19.65. In terms of profitability, MED's ROE is -0.10%, compared to SCI's ROE of +0.39%. Regarding short-term risk, MED is more volatile compared to SCI. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check SCI's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, FTDR has a market cap of 5.2B. Regarding current trading prices, MED is priced at $10.51, while FTDR trades at $74.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas FTDR's P/E ratio is 17.92. In terms of profitability, MED's ROE is -0.10%, compared to FTDR's ROE of +1.00%. Regarding short-term risk, MED is more volatile compared to FTDR. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check FTDR's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, HRB has a market cap of 4.7B. Regarding current trading prices, MED is priced at $10.51, while HRB trades at $37.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas HRB's P/E ratio is 7.09. In terms of profitability, MED's ROE is -0.10%, compared to HRB's ROE of -2.26%. Regarding short-term risk, MED is more volatile compared to HRB. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check HRB's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, CVSA has a market cap of 4.3B. Regarding current trading prices, MED is priced at $10.51, while CVSA trades at $127.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas CVSA's P/E ratio is 16.30. In terms of profitability, MED's ROE is -0.10%, compared to CVSA's ROE of +0.17%. Regarding short-term risk, MED is more volatile compared to CVSA. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check CVSA's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, BFAM has a market cap of 3.7B. Regarding current trading prices, MED is priced at $10.51, while BFAM trades at $70.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas BFAM's P/E ratio is 15.23. In terms of profitability, MED's ROE is -0.10%, compared to BFAM's ROE of +0.14%. Regarding short-term risk, MED is less volatile compared to BFAM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check BFAM's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, DSEY has a market cap of 2.7B. Regarding current trading prices, MED is priced at $10.51, while DSEY trades at $8.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas DSEY's P/E ratio is -14.47. In terms of profitability, MED's ROE is -0.10%, compared to DSEY's ROE of -0.23%. Regarding short-term risk, MED is more volatile compared to DSEY. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check DSEY's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, MCW has a market cap of 2.3B. Regarding current trading prices, MED is priced at $10.51, while MCW trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas MCW's P/E ratio is 21.52. In terms of profitability, MED's ROE is -0.10%, compared to MCW's ROE of +0.10%. Regarding short-term risk, MED is more volatile compared to MCW. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check MCW's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, ROVR has a market cap of 2B. Regarding current trading prices, MED is priced at $10.51, while ROVR trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas ROVR's P/E ratio is 183.25. In terms of profitability, MED's ROE is -0.10%, compared to ROVR's ROE of -0.07%. Regarding short-term risk, MED is more volatile compared to ROVR. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check ROVR's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, CSV has a market cap of 622.5M. Regarding current trading prices, MED is priced at $10.51, while CSV trades at $39.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas CSV's P/E ratio is 12.65. In terms of profitability, MED's ROE is -0.10%, compared to CSV's ROE of +0.18%. Regarding short-term risk, MED is more volatile compared to CSV. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check CSV's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, KLC has a market cap of 499.8M. Regarding current trading prices, MED is priced at $10.51, while KLC trades at $4.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas KLC's P/E ratio is 8.27. In terms of profitability, MED's ROE is -0.10%, compared to KLC's ROE of -0.55%. Regarding short-term risk, MED is less volatile compared to KLC. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check KLC's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, FWDI has a market cap of 307.2M. Regarding current trading prices, MED is priced at $10.51, while FWDI trades at $3.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas FWDI's P/E ratio is -0.15. In terms of profitability, MED's ROE is -0.10%, compared to FWDI's ROE of -1.42%. Regarding short-term risk, MED is less volatile compared to FWDI. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check FWDI's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, EM has a market cap of 303.1M. Regarding current trading prices, MED is priced at $10.51, while EM trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas EM's P/E ratio is -119.50. In terms of profitability, MED's ROE is -0.10%, compared to EM's ROE of -0.01%. Regarding short-term risk, MED is more volatile compared to EM. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check EM's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, MIN has a market cap of 278.2M. Regarding current trading prices, MED is priced at $10.51, while MIN trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas MIN's P/E ratio is 12.32. In terms of profitability, MED's ROE is -0.10%, compared to MIN's ROE of +0.06%. Regarding short-term risk, MED is more volatile compared to MIN. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check MIN's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, WW has a market cap of 159.9M. Regarding current trading prices, MED is priced at $10.51, while WW trades at $15.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas WW's P/E ratio is -2.39. In terms of profitability, MED's ROE is -0.10%, compared to WW's ROE of +3.34%. Regarding short-term risk, MED is less volatile compared to WW. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check WW's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, LGCY has a market cap of 144.2M. Regarding current trading prices, MED is priced at $10.51, while LGCY trades at $11.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas LGCY's P/E ratio is 18.39. In terms of profitability, MED's ROE is -0.10%, compared to LGCY's ROE of +0.19%. Regarding short-term risk, MED is more volatile compared to LGCY. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check LGCY's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, RGS has a market cap of 68.1M. Regarding current trading prices, MED is priced at $10.51, while RGS trades at $27.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas RGS's P/E ratio is 11.31. In terms of profitability, MED's ROE is -0.10%, compared to RGS's ROE of +0.60%. Regarding short-term risk, MED is more volatile compared to RGS. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check RGS's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, XSPA has a market cap of 54.5M. Regarding current trading prices, MED is priced at $10.51, while XSPA trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas XSPA's P/E ratio is 21.83. In terms of profitability, MED's ROE is -0.10%, compared to XSPA's ROE of +24.20%. Regarding short-term risk, MED is less volatile compared to XSPA. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check XSPA's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, XWEL has a market cap of 6.7M. Regarding current trading prices, MED is priced at $10.51, while XWEL trades at $1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas XWEL's P/E ratio is -0.33. In terms of profitability, MED's ROE is -0.10%, compared to XWEL's ROE of +2.89%. Regarding short-term risk, MED is less volatile compared to XWEL. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check XWEL's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, EJH has a market cap of 5.3M. Regarding current trading prices, MED is priced at $10.51, while EJH trades at $1.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas EJH's P/E ratio is -0.03. In terms of profitability, MED's ROE is -0.10%, compared to EJH's ROE of +0.01%. Regarding short-term risk, MED is less volatile compared to EJH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check EJH's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, MRM has a market cap of 5.1M. Regarding current trading prices, MED is priced at $10.51, while MRM trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas MRM's P/E ratio is 1.18. In terms of profitability, MED's ROE is -0.10%, compared to MRM's ROE of -0.68%. Regarding short-term risk, MED is less volatile compared to MRM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check MRM's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, BYAH has a market cap of 779.1K. Regarding current trading prices, MED is priced at $10.51, while BYAH trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas BYAH's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.10%, compared to BYAH's ROE of -5.91%. Regarding short-term risk, MED is less volatile compared to BYAH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check BYAH's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, IVP has a market cap of 85.8K. Regarding current trading prices, MED is priced at $10.51, while IVP trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas IVP's P/E ratio is -0.00. In terms of profitability, MED's ROE is -0.10%, compared to IVP's ROE of -5.20%. Regarding short-term risk, MED is more volatile compared to IVP. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check IVP's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, TRNR has a market cap of 79.9K. Regarding current trading prices, MED is priced at $10.51, while TRNR trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas TRNR's P/E ratio is -0.04. In terms of profitability, MED's ROE is -0.10%, compared to TRNR's ROE of -2.34%. Regarding short-term risk, MED is less volatile compared to TRNR. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check TRNR's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, NEBCU has a market cap of 0. Regarding current trading prices, MED is priced at $10.51, while NEBCU trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas NEBCU's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.10%, compared to NEBCU's ROE of -0.00%. Regarding short-term risk, MED is less volatile compared to NEBCU. This indicates potentially lower risk in terms of short-term price fluctuations for MED.Check NEBCU's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, STON has a market cap of 0. Regarding current trading prices, MED is priced at $10.51, while STON trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas STON's P/E ratio is -6.64. In terms of profitability, MED's ROE is -0.10%, compared to STON's ROE of +0.48%. Regarding short-term risk, MED is more volatile compared to STON. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check STON's competition here

MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 116.6M. In comparison, TMX has a market cap of 0. Regarding current trading prices, MED is priced at $10.51, while TMX trades at $37.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -11.53, whereas TMX's P/E ratio is 70.13. In terms of profitability, MED's ROE is -0.10%, compared to TMX's ROE of +0.05%. Regarding short-term risk, MED is more volatile compared to TMX. This indicates potentially higher risk in terms of short-term price fluctuations for MED.Check TMX's competition here